[1] 周召, 阿卜杜热西提·阿卜来提, 顾智强, 等.尽早启动抗病毒治疗降低慢性HBV感染者肝细胞癌发生风险. 临床肝胆病杂志, 2023, 39(01):31-36.
[2] Tu T, Budzinska MA, Shackel NA, et al. HBV DNA Integration: Molecular Mechanisms and Clinical Implications. Viruses, 2017, 9(4):75.
[3] 王雷婕, 曾婉嘉, 李德瑶, 等. 乙型肝炎病毒蛋白对宿主免疫的影响及其临床意义. 中华肝脏病杂志, 2021, 29(07):625-630.
[4] Baudi I, Kawashima K, Isogawa M. HBV-Specific CD8+ T-Cell Tolerance in the Liver. Front Immunol, 2021, 12:721975.
[5] Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol, 2015, 15(8):486-499.
[6] Mason WS, Gill US, Litwin S, et al. HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. Gastroenterology, 2016, 151(5):986-998.
[7] Ning J, Wang J, Zheng H, et al. Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups. Emerg Microbes Infect, 2022, 11(1):1356-1370.
[8] Le Bert N, Gill US, Hong M, et al. Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection. Gastroenterology, 2020, 159(2):652-664.
[9] Aggarwal A, Odorizzi PM, Brodbeck J, et al. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells. JHEP Rep, 2022, 5(4):100664.
[10] 刘燕娜, 李明蔚, 王雷婕, 等. 扩大慢性乙型肝炎抗病毒治疗应重视ALT正常、年龄≤30岁的HBeAg阴性慢性HBV感染者. 临床肝胆病杂志, 2022, 38(07):1477-1481.
[11] Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol, 2014, 61(4):777-84.
[12] Wang Q, Li H, Ding D, et al. Upgrade Combination Response Is Limited by Prolonged Nucelos(t)ide Analogue Therapy in HBeAg-positive Chronic Hepatitis B: A Real-life Study. J Clin Transl Hepatol, 2018, 6(1):11-17.
[13] 鲁凤民, 王杰, 陈香梅, 等. 乙型肝炎病毒RNA病毒样颗粒的发现及其对抗病毒治疗临床实践的潜在影响. 中华肝脏病杂志, 2017, 25 (2):105-110.
[14] Mo Z, Xie D, Fu L, et al. Functional cure based on pegylated interferon ɑ-2b therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China)-4 years data update. AASLD, 2022.
[15] Wang G, Cui Y, Xie Y, et al. Effects of Subcutaneous PD-L1 Antibody ASC22 (Envafolimab) Plus nucleos(t)ide analogs on HBsAg reduction in patients with chronic hepatitis B infection are correlated with pre-treatment HBsAg level. APASL, 2023.
[16] Yuen MF, Lim SG, Plesniak R, et al. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. N Engl J Med, 2022, 387(21):1957-1968.
[17] Jeng WJ, Chen YC, Chien RN, et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology, 2018, 68(2):425-434.
[18] Hirode G, Choi HSJ, Chen CH, et al. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology, 2022, 162(3):757-771.
[19] 李德瑶, 陆丹娟, 鲁凤民. 反义寡核苷酸治疗慢性乙肝,相对确定的有限疗效与尚未明确的机制. 中华肝脏病杂志,2023. |
